Previous close | 3.6600 |
Open | 3.6900 |
Bid | 3.7200 x 200 |
Ask | 3.7800 x 500 |
Day's range | 3.6350 - 3.8500 |
52-week range | 1.2500 - 4.6500 |
Volume | |
Avg. volume | 336,145 |
Market cap | 283.969M |
Beta (5Y monthly) | 1.99 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0700 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.47 |
LOS ANGELES, April 30, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces an ingredient partnership with Solgar®, a Nestlé Health Science brand. Solgar’s inaugural NAD+ supplement, Solgar Cellular Nutrition Cellular Energy, features ChromaDex’s patented nicotinamide riboside (NR) ingredient, NIAGEN® to support NAD+ levels for cellular health. This product marks a significant milestone in the health and welln
LOS ANGELES, April 25, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship consumer supplement, Tru Niagen®, is now available at The Vitamin Shoppe retail locations nationwide and online at www.vitaminshoppe.com. This retail expansion adds Tru Niagen to the shelves of 700 locations of The Vitamin Shoppe and Super Supplements, enhancing consumer access to the number one healthy-aging NAD+ sup
LOS ANGELES, April 24, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.